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1. Introduction  
The formation of new blood vessels, or neovascularization, involves multiple processes, 
including cell proliferation and migration, cell-cell and cell-matrix adhesion, and tube 
morphogenesis. Neovascularization can occur through one of two events: vasculogenesis, 
the de novo formation of blood vessels from angioblasts; or angiogenesis, the extension of 
new vessels from a pre-existing vasculature. Among these, angiogenesis in particular is 
relevant throughout life; its dysregulation has been causally related to several disorders that 
involve malignancy, inflammation, and ischemia. Angiogenesis is thought to depend on a 
set of signaling proteins – including certain kinases, integrins and vascular endothelial 
growth factor receptor-2 (VEGFR2) – that are enriched in specific plasma membrane 
domains. Both physiological and pathological angiogenesis rely on intracellular trafficking, 
a process that governs signaling by such proteins, as well as cell motility.  
In this chapter, we discuss our current understanding of angiogenesis from the perspective 
of trafficking of the membrane components that are responsible for endothelial-cell (EC) 
dynamics. 
2. Angiogenesis: Mechanism and importance  
The vascular system carries out a variety of functions vital to vertebrates. It delivers oxygen 
and nutrients to tissues and organs. It is required for waste disposal, including the 
detoxification of toxic metabolites in the liver and their excretion through kidney. It is 
needed for the onset of immune responses against pathogens, since it transports immune 
cells to the site of infection and/or inflammation. Finally, its constituent vessels produce 
instructive signals for organogenesis. 
Blood vessels are the main component of the vascular system and comprise: an EC 
monolayer that lines the vessel lumen, vascular smooth muscle cells that surround the EC 
monolayer, and a basement membrane that covers the vascular tube (Figure 1). The larger 
vessels, arteries and veins are stabilized by a thick layer of vascular smooth muscle cells, 
whereas the medium-sized vessels are supported by mural cells, for example pericytes 
(Gerhardt and Betsholtz, 2003). 
The vascular system is among the earliest organ systems to develop in embryos; it first 
emerges when haemangioblast progenitors proliferate, migrate and differentiate into  
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ECs and form a primitive vascular plexus. The formation of new blood vessels, or 
neovascularization, then occurs either through vasculogenesis or angiogenesis, as mentioned 
above. 
 
Fig. 1. Schematic representation of a mature blood vessel. Endothelial cells at the luminal 
side line tubular blood vessel. The smooth muscle cells and the pericytes that remain in 
contact with the endothelial cell lining through the basement membrane strengthen this 
tubular structure. 
2.1 Vasculogenesis 
Vasculogenesis, defined as de novo formation of blood vessels from precursor cells, starts 
with differentiation of precursor cells (angioblasts) into ECs and a primitive vascular 
network. In the first phase of vasculogenesis (during gastrulation), the splanchnic 
mesoderm gives rise to hemangioblasts, which are presumed to be the common progenitors 
of ECs and blood cells (Baron, 2001; Choi, 2002), and subsequently the outer cells of the 
blood island differentiate into angioblasts. In the second phase, angioblasts differentiate into 
ECs. In the third and final phase, the ECs participate in tube formation, giving rise to the 
primitive vascular plexus (Figure 2). Growth factor, fibroblast growth factor 2 (FGF2) 
generates hemangioblasts from the mesoderm, whereas vascular endothelial growth factor 
(VEGF) and its receptor, VEGFR, cooperate in hemangioblast generation and tube 
formation, and Angiopoietin-1 (Ang-1) regulates the connection between ECs and pericytes 
(Hiratsuka, 2011). 
2.2 Angiogenesis 
Angiogenesis, the establishment of new vessels from a pre-existing vasculature, starts with 
stimulation of ECs that line the luminal surface of blood vessels. The process of angiogenesis 
can be classified into two types: “sprouting” and “nonsprouting” (Risau, 1997). Sprouting 
angiogenesis refers to a process that entails proteolytic degradation of the extracellular 
matrix, the migration and proliferation of cells, the formation of a lumen, and maturation of 
ECs into functional capillaries. Specifically, ECs in pre-existing vessels respond to activation 
by a stimulatory molecule supplied by neighboring cells (e.g. VEGF), by producing a 
protease that degrades the surrounding basement membrane, to facilitate EC migration 
towards stimulatory signal. The sprout is comprised of a growth-arrested leading tip cell 
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and proliferating stalk cells (Gerhardt et al., 2003). The tips cells are migratory and extend 
long filopodia that guide the sprouts towards the stimulus. Subsequently, the sprout 
anastomoses with other newly formed vessels to allow circulation. The basement membrane 
reassembles pericytes and gets recruited to newly formed vessels (Figure 2). Sprouting 
angiogenesis occurs during yolk sac and embryo development, and later during brain 
development (Scappaticci, 2002). Non-sprouting angiogenesis is a process that occurs by 
invagination involving EC proliferation within a vessel, and results in an enlarged lumen 
that can be split by transcapillary or by the fusion and splitting of capillaries. Non-sprouting 
angiogenesis occurs mainly during development of the lung and heart (Scappaticci, 2002).  
Both sprouting and non-sprouting angiogenesis contribute to vessel formation in the adult, 
via a process known as “adult vasculogenesis”. This process is thought to rely on 
endothelial progenitor cells (EPCs) that originate from the bone marrow. While circulating 
in the blood, EPCs are incorporated into vessels at the site of angiogenesis (Caplice and 
Doyle, 2005).  
 
Fig. 2. Schematic outline of vasculogenesis (above) and angiogenesis (below). Both 
sprouting and non-sprouting mechanism of angiogenesis are shown. 
2.3 Pathological angiogenesis 
The process of angiogenesis is highly regulated in healthy adults and occurs only rarely, for 
example during ovulation and the endometrial growth that is central to the menstrual cycle. 
Angiogenesis is also required for wound healing, and ceases once this process is completed. 
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Since vessels nourish nearly every organ of the body the strict limitation of angiogenesis to 
such contexts is essential; deviation from normal vessel growth – in either direction – leads 
to fatal disease. Excess angiogenesis is characteristic of conditions such as retinopathy, 
rheumatoid arthritis, psoriasis and tumor growth (Folkman, 1995), and insufficient 
angiogenesis is a feature of ischemic heart and limb disease, stroke and gastrointestinal 
ulcers (Carmeliet and Jain, 2000).  
The process of angiogenesis plays a crucial role in cancer metastasis – the major cause of 
mortality in cancer patients. In tumor diseases, angiogenesis is stimulated by the secretion of 
signaling molecules, e.g. VEGFA, by either the tumor cells themselves or tumor-infiltrating 
macrophages. In most cancers, tumor angiogenesis is crucial for disease progression, as it 
supplies the tumor cells with nutrients and oxygen, enabling them to survive and spread 
(Folkman, 2002). Notably, tumor-supporting vessels tend to be disorganized and leaky; thus 
vessel function is suboptimal and angiogenesis is further stimulated by hypoxia-driven 
expression of VEGFA in the tumor tissue. These findings have stimulated great interest in 
targeting tumor vessels as a means of developing novel cancer therapies. Indeed, intensive 
research efforts toward this end have revealed that, in patients with metastatic colorectal 
cancer, supplementing chemotherapy with a neutralizing antibody against VEGFA 
(Avastin/Bevacizumab) results in significantly improved survival (McCarthy, 2003). 
Angiogenesis can also be regulated by microRNA (miRNA) (Wang and Olson, 2009). 
MicroRNA is a class of highly conserved, single stranded, non-coding small RNAs 
influencing gene expression by inhibiting translation of protein from mRNA or by 
promoting the degradation of mRNA (Bartel, 2004; Kim, 2005). The direct evidence of 
miRNA importance in angiogenesis was provided by observation of defective vascular 
remodeling during developmental angiogenesis in hypomorphic mouse line with EC-
specific deletion of Dicer, one of key enzymes involved in miRNA generation (Otsuka et al., 
2008; Yang et al., 2005). Endothelial cell primarily express miRNA-221/222, miRNA-21, the 
Let-7 family, the miR-17-92 cluster, the miRNA-23-24 cluster, and miRNA-126 (Harris et al., 
2008; Kuehbacher et al., 2007; Suarez et al., 2007). miRNA-210 which gets activated upon 
hypoxia is an important regulator of EC survival, migration and differentiation during 
angiogenesis (Fasanaro et al., 2008). miRNA-210 overexpression under normoxic conditions 
stimulates angiogenesis and VEGF-induced cell migration whereas its blockade by anti-
mRNA inhibits tube formation stimulated by hypoxia (Fasanaro et al., 2008). miRNA-210 
may play an important role in pathological angiogenesis  since hypoxia is associated with 
tumor development and organ ischemia. miRNA-21 and miRNA-31 are the other pro-
angiogenic miRNAs which are upregulated in various various cancers to stimulate invasion 
and metastasis in cancer (Tsai et al., 2009). 
3. Ligands and receptors in angiogenesis 
At the molecular level, the initiation of vascular development is dependent on a number of 
cell-surface receptors and their respective ligands. Upon binding to a wide range of peptide 
growth factors, members of the receptor tyrosine kinase (RTK) family of transmembrane 
proteins transduce proliferative and morphogenic signals, thereby fine-tuning the 
orchestration of vascular remodeling and angiogenic processes. Although angiogenesis is 
controlled by a wide range of extracellular signals, the most potent pro-angiogenic signaling 
is initiated by binding of VEGF (vascular endothelial growth factor) to EC-resident VEGF 
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receptors (VEGFRs) like VEGFR1 [Flt (Fms-like tyrosine kinase)-1], VEGFR2 [Flk-1 (fetal 
liver kinase 1)/KDR (kinase insert domain receptor)] and VEGFR3 (Flt-4) (Zachary, 2003). 
Remodeling from existing vessels during angiogenesis is governed by VEGF-mediated EC 
proliferation, and their sprouting from points of loose contact between capillaries and the 
extracellular matrix. The nascent capillary network then matures through the actions of 
TGF-┚ and platelet-derived growth factor (PDGF). The arterial and venous ECs within the 
final primary capillary express Ephrin B2 and its receptor EphB4, respectively, in their cell 
membranes; this enables correct fusion between arterial and venous vessels. 
3.1 The VEGF-VEGFR system coordinates the process of angiogenesis 
3.1.1 VEGF 
The VEGF family is a branch of the PDGF/VEGF supergene family and its members have a 
homodimeric structure (Ferrara and Davis-Smyth, 1997). The VEGF family consists of five 
related growth factors: VEGFA, VEGFB, VEGFC, VEGFD and PlGF (placental growth 
factor). Although VEGFs are homodimeric polypeptides, naturally occurring heterodimers 
have also been reported (DiSalvo et al., 1995). VEGFA, which was also isolated as vascular 
permeability factor (VPF), is alternatively spliced to generate VEGFA121, VEGFA145, 
VEGFA165 and VEGFA189 (the numbers indicate final residue in each polypeptide in 
humans). Alternative splicing and processing regulates ligand binding to VEGF receptors, 
heparan sulfate and neuropilins (NRPs) (Grunewald et al., 2010). VEGFA165 and VEGFA189 
bind to both heparan sulfate and NRP1. VEGFA plays an important role in the proliferation 
and migration of ECs, and also acts on monocytes and macrophages, neurons, cancer cells, 
and kidney epithelial cells. VEGFA is known to be regulated by hypoxia-inducible factor 
(HIF) (Germain et al., 2010), an event that leads to increased expression during embryonic 
development and wound healing, and also in the context of cancer. VEGFA produced by 
most parenchymal cells, act in paracrine manner on adjacent ECs to regulate signaling by 
the VEGF receptors. Autocrine VEGFA is essential for EC survival (Lee et al., 2007), and is 
consistent with their requirement for complete development of the vasculature in mice; both 
homozygosity and heterozygosity for knockout of the VEGFA gene result in embryonic 
lethality characterized by incomplete development of the vasculature (Carmeliet et al., 1996; 
Ferrara et al., 1996). The biological activity of VEGF is manifested after it binds to VEGF 
receptors, which are of 3 different types in human, and bind VEGF with distinct affinities. 
3.2 VEGF receptors 
Orthologs of each of the VEGF receptor tyrosine kinases (VEGFRs) – namely VEGFR1, 
VEGFR2 and VEGFR3 – have been identified in humans, mice and other mammals. 
Structurally, the VEGFRs have a common organization consisting of: an extracellular, 
ligand-binding domain that features 7 immunoglobulin (Ig)–like loops, a transmembrane 
domain; a juxtamembrane domain; a split kinase domain and a C-terminal tail (Figure 3). 
Structurally, the VEGFRs are distantly related to the PDGFRs, which have five extracellular 
Ig-like domains (Matthews et al., 1991; Terman et al., 1991). All three VEGFRs undergo 
alternative splicing to generate more than one receptor form. The truncated form of 
VEGFR1, known as soluble VEGFR1 (sVEGR1, sFlt-1) (Kendall and Thomas, 1993), is 
implicated as causative agent in preeclampsia, a major disorder that can occur during 
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pregnancy (Levine et al., 2004). A naturally occurring soluble form of VEGFR2 has also been 
described; it could potentially arise as a result of alternative splicing or through proteolytic 
processing (Ebos et al., 2004). In humans, alternative splicing of VEGFR3 generates two 
isoforms with distinct C-terminal tails (Hughes, 2001). 
 
Fig. 3. VEGF receptors and their ligands. Schematic presentation of VEGF receptors 
(VEGFR1, VEGFR2 and VEGFR3). The signaling domain of all three receptors is present 
within cytosol. The Ig-like domains of VEGFRs are involved in VEGF binding, shown in 
elliptical structures that are present extracellularly. More than one kind of VEGF can bind to 
one receptor with different affinities. 
3.2.1 VEGFR1 
VEGFR1  (also known as Flt1 in mouse) is a glycoprotein of 150-184 kDa (de Vries et al., 
1992; Shibuya et al., 1990) that gets activated upon binding of VEGFA, VEGFB and PLGF. 
VEGFR1 is expressed in vascular ECs at relatively high levels, throughout development and 
in the adult (Peters et al., 1993). It is also expressed in various other cell types such as 
monocytes, macrophages, human trophoblasts, renal mesangial cells, vascular smooth 
muscle cells, dendritic cells and a variety of human tumor-cell types (Barleon et al., 1996; 
Dikov et al., 2005; Sawano et al., 2001).  
Alternative splicing of VEGFR1 generates soluble VEGFR1 (sVEGFR1), which is abundantly 
expressed in the placenta. Although the affinity of VEGFR1 for VEGFA is greater than that 
of VEGFR2, VEGFR1 transduces only weak signals for EC and pericyte growth and survival, 
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as well as for macrophage migration (Barleon et al., 1996; Nomura et al., 1995). In response 
to ligand binding, VEGFR1 undergoes autophosphorylation at various tyrosines within the 
intracellular domain (TYRs1169, 1213, 1242, 1327, 1333) (Ito et al., 1998; Sawano et al., 1997). 
Phosphorylation of TYR1169 allows binding and activation of phospholipase C (PLC)1, 
which regulates EC proliferation via the mitogen-activated protein kinase (MAPK) pathway 
(Sawano et al., 1997). Tyr1213 binds a variety of SH2-containing proteins, including PLCγ, 
growth-factor-receptor bound protein (GRB) 2, non-catalytic region of tyrosine kinase 
adaptor protein (Nck) and SH2-domain-containing protein tyrosine phosphatase 2 (SHP-2) 
(Igarashi et al., 1998; Ito et al., 1998). Tyr1309 is however phosphorylated in response to 
PLGF but not VEGF (Autiero et al., 2003) (Figure 4).  Although the exact role of VEGFR1  
 
Fig. 4. VEGFR1 tyrosine phosphorylation and signaling. Schematic presentation of 
intracellular dimerized VEGFR1. VEGFA/VEGFB binding induces tyrosine phosphorylation 
of VEGFR1 at different tyrosine (TYR) positions shown in yellow ellipses. PLGF binding 
stimulates phosphorylation at TYR1309 shown in orange ellipse. Signaling molecules 
(shown within boxes) binds to certain phosphorylated tyrosine residues (circled P) and 
activates downstream signaling events leading to specific physiological outcome (shown in 
purple boxes) required for vascular permeability and endothelial cell regulation. PLC┛, 
phospholipase C-┛; MAPK, mitogen-activated protein; RACK1, receptor for activated C-
kinase 1; SHP2, SH2-domain-containing protein tyrosine phosphatase 2. 
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remains a subject of debate, studies using VEGFR1-neutralizing antibodies have implicated 
this receptor in actin reorganization within, and the migration of ECs (Kanno et al., 2000), 
and suggested that receptor for activated C-kinase 1 (RACK1) is its downstream effector in 
this context (Wang et al., 2011). VEGFR1-dependent activation of PI3K/Akt may play a role 
in EC differentiation and organization (Huang et al., 2001) (Figure 4). Under in vitro 
conditions, VEGFR1 and VEGFR2 are known to form heterodimers on cells co-expressing 
these receptors (Huang et al., 2001), so it is believed that VEGFR1 can regulate EC functions 
via cross-talk with VEGFR2, through dimerization as a result of VEGFA binding to both. 
Binding of PLGF can also lead to crosstalk between VEGFR2 and VEGFR1 through 
transphosphorylation, leading to sensitization of VEGFR2 subsequent to activation by 
VEGFA (Autiero et al., 2003). Soluble VEGFR1 (sVEGFR1, sFlt1) can negatively influence 
vascular development, either by sequestering VEGFA from signaling receptors or by 
forming non-functional heterodimers with VEGFR2 (Kendall et al., 1994). Although, 
VEGFR1 and sVEGFR1 are considered VEGF decoys that control signaling by VEGFR1 and 
the formation of angiogenic sprouts (Kappas et al., 2008), the importance of VEGFR1 in 
angiogenesis is demonstrated by the fact that the VEGR1 null (vegfr1-/-) mouse dies at 
embryonic day 9, due to increased proliferation of ECs, disorganization and dysfunction of 
the vascular system (Fong et al., 1995). 
3.2.2 VEGFR2 
VEGFR2 (also known as KDR or Flk-1) is generally accepted to be the main receptor tyrosine 
kinase responsible for transducing the angiogenic activities of VEGFA, a factor that stimulates 
vascular-cell survival/growth and promotes angiogenesis. VEGFR2 knockout results in 
embryonic lethality due to deficiencies in vasculogenesis and hematopoiesis (Shalaby et al., 
1995). VEGFR2 is highly expressed in vascular endothelial progenitors during early 
embryogenesis and generates a variety of angiogenic signals, not only for the proliferation of 
ECs but also their migration and morphogenesis, and as such has an important role in vascular 
tube formation. VEGFR2 expression is upregulated under conditions that trigger pathological 
angiogenesis, such as in tumors (reviewed in (Matsumoto and Claesson-Welsh, 2001). The 
binding of VEGF to VEGFR2 leads to receptor dimerization and promotes EC differentiation, 
proliferation, migration and vascular-tube formation. Both homo- and heterodimerization 
occurs following the trans-phosphorylation of tyrosine in the receptor intracellular domain. 
The major phosphorylation sites on VEGFR2 are TYR951 (in the kinase-insert domain), 
TYR1054 and TYR1059 (within the kinase domain), and TYR1175 and TYR1214 (in the C-
terminal domain) (Matsumoto et al., 2005; (Takahashi et al., 2001). Additional phosphorylation 
sites on VEGFR2 have been identified at postions 1223, 1305, 1309 and 1319, but their function 
remains to be established (Matsumoto et al., 2005). Although TYR801 within the 
juxtamembrane can be phosphorylated when the intracellular portion of VEGFR2 is tested in 
isolation (Solowiej et al., 2009), its phosphorylation in the context of the intact protein has not 
yet been demonstrated. Phosphorylation at TYR951, within the kinase-insert domain, leads to 
binding and tyrosine  phosphorylation of the SH2-domain–containing signaling molecule T-
cell specific adapter (TSAd)(Matsumoto et al., 2005). TSAd, which is equipped with Src 
Homology 2 (SH2) and protein tyrosine binding (PTB) domains, in turn associates with the 
cytoplasmic tyrosine kinase Src, thereby regulating actin stress fiber organization and the 
migratory responses of ECs to VEGFA (Figure 5). Phosphorylation at TYR1054 and TYR1059, 
both of which are located within the kinase domain activation loop (Kendall et al., 1999), is 
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preceded by autophosphorylation at TYR801 (Solowiej et al., 2009). Phosphorylation at 
TYR1059 induces Src binding, which in turn phosphorylates TYR1175 of VEGFR2, as well as 
residues within downstream signal transducers, such as the actin binding protein IQ-motif-
contaning GTPase-activating protein 1 (IQGAP1), which is implicated in the regulation of cell-
cell contacts, proliferation and migration (Meyer et al., 2008; Yamaoka-Tojo et al., 2006). 
 
Fig. 5. VEGFR2 tyrosine phosphorylation and signaling. Schematic presentation of 
dimerized VEGFR2. VEGFA/VEGFB/VEGFC binding induces tyrosine phosphorylation of 
VEGFR2 at different tyrosine (TYR) positions shown in ellipses. Signaling molecules (shown 
within boxes) binds to certain phosphorylated TYR residues (circled P) and activates 
network of downstream signaling events required for variety of physiological outcomes 
(shown in purple boxes) essential during vasculogenesis and angiogenesis. 
Phosphorylation at TYR1175 is required for the binding of PLC, which mediates activation 
of the mitogen-activated protein kinase (MAPK)/extracellular-signal-regulated kinase-1/2 
(ERK1/2) cascade and the proliferation of ECs (Takahashi et al., 2001). Binding of PLC 
stimulates the protein kinase C (PKC) pathway, leading to inositol triphosphate generation 
and calcium mobilization. In addition to interacting with PLC, phosphorylated TYR1175 
binds to the SH2-domain–containing adaptor protein B (SHB) and Src homology and 
collagen homology (Sck/SHC) (Holmqvist et al., 2004; Warner et al., 2000). SHB binds to 
Tyrosine-phosphorylated focal adhesion kinase (FAK) in VEGF-treated cells (Abu-Ghazaleh 
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et al., 2001) and thereby contributes to EC attachment and migration (Holmqvist et al., 2003). 
The binding of SHC to TYR1175-phosphorylated VEGFR2 is believed to control Ras 
activation and mitogenicity in response to VEGF (Meadows et al., 2001). 
3.2.3 VEGFR3  
VEGFR3, also denoted Flt4, is a protein with a molecular weight of around 195 kDa, and 
becomes activated when bound to VEGFC or VEGFD. VEGFR3 is an essential protein; its 
inactivation results in embryonic death at E9.5, due to abnormal remodeling of the primary 
vascular plexus (Dumont et al., 1998). Although VEGFR3 plays a role in vascular 
development in the early embryo, its expression is later largely confined to ECs of the 
lymphatic system (Kaipainen et al., 1995). The exception is when its expression is induced in 
vascular ECs during active phases of angiogenesis, for example in the tumor vasculature or 
the endothelial tip cells of angiogenic sprouts in the retina (Tammela et al., 2008). VEGFR3 
has five tyrosine phosphorylation sites – at positions 1230, 1231, 1265, 1337 and 1363 in the 
C-terminal tail (Dixelius et al., 2003) – that are activated and phosphorylated upon binding 
of VEGFC or VEGFD. TYR1337 when phosphorylated is known to bind to Shc and Grb2 to 
initiate signaling by the MAPK pathway. Both TYR1063 and TYR1068, which are located 
within the kinase activation domain, are crucial for kinase activity. Phosphorylation of 
TYR1230 and TYR1231 creates a docking site for SHC–GBR2, which promotes signaling by 
the ERK1/2 and PI3K/Akt pathways (Figure 6). Phosphorylated TYR1063 has been shown 
to interact with adaptor protein C10 regulator of kinase (CRK I/II), which activates the c-Jun 
N-terminal kinase (JNK) pathway to promote cell survival (Salameh et al., 2005). 
3.2.4 Neuropilins (NRP) 
The cell-surface glycoprotein neuropilin is a transmembrane protein with a small 
cytoplasmic tail that lacks intrinsic catalytic function (Fujisawa et al., 1997). The neuropilin 
homolog NRP1 is expressed in arteries, whereas NRP2, is expressed in the venous and 
lymphatic vessels (Yuan et al., 2002). NRP1 was originally identified as a receptor for the 
collapsin/semaphorin family of neuronal guidance molecule (Chen et al., 1997). Later it was 
reported to also be expressed in ECs, where it acts as a coreceptor for VEGFA164 and 
VEGFA165 in mice and humans, respectively (Miao et al., 1999; Soker et al., 1998). NRP1 
modulates VEGFR signaling, leading to enhanced survival and migration of ECs in vitro 
(Favier et al., 2006). NRP1 has also been implicated in VEGFR2-mediated vascular 
permeability (Becker et al., 2005) and VEGFA-induced vessel sprouting and branching 
(Kawamura et al., 2008). Although the exact influence of NRP1 on VEGFA mediated 
VEGFR2 signaling remains to be deciphered, the importance of NRP1 in angiogenesis was 
established by the fact that overexpression or deletion of NRP1 in mice leads to embryonic 
lethality and vascular abnormalities (Kawasaki et al., 1999). Neuropilin is also expressed in 
tumors and is believed to enhance tumor angiogenesis (Miao et al., 2000); it probably does 
so by stabilizing VEGF/VEGFR signaling on adjacent cell in trans. 
3.3 Role of the extracellular matrix (ECM) in endothelial-cell interactions during 
angiogenesis 
The angiogenic process is influenced not only by ligand/receptor systems, but also overall 
composition of extracellular matrix (ECM) surrounding the vasculature. Indeed, the ECM 
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Fig. 6. VEGFR3 tyrosine phosphorylation and signaling. Schematic presentation of 
intracellular dimerized VEGFR3. VEGFC/VEGFD binding induces tyrosine 
phosphorylation of VEGFR3 at different tyrosine (TYR) positions shown in green ellipses. 
Signaling molecules (shown within boxes) binds to certain phosphorylated tyrosine residues 
(circled P) and activates network of downstream signaling events required for variety of 
physiological outcomes (shown in purple boxes) essential during vasculogenesis and 
angiogenesis 
provides an essential connection between ECs and the surrounding tissues and affect 
angiogenesis either positively or negatively (Nyberg et al., 2005). ECs are attached to a 
basement membrane (BM), which forms a continuous coat around the vessels. The main 
components of the vascular BM are type IV collagen, laminins, fibronectin, heparan-
sulphate proteoglycans and nidogens. The BM provides structural support to the ECs 
(Kalluri, 2003), and interaction of ECs with components in the BM is important for 
maintaining integrity of the vessel wall (Hallmann et al., 2005). When ECs are exposed to 
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angiogenic growth factors such as VEGFA, several kind of matrix-degrading enzymes, such 
as matrix metalloproteinases, dissolve the BM. Matrix-degrading enzymes are produced by 
ECs and stromal cells, as well as by tumor and inflammatory cells (Egeblad and Werb, 2002). 
Endothelial sprouting is activated not only by growth factors, but also signals from the 
matrix proteins. Degradation of the BM reveals so-called cryptic sites that can activate the 
angiogenic properties of ECs. As the BM is degraded and vascular permeability increases, 
the blood-clotting protein fibrinogen leaks out of the vessels and polymerizes into a fibrin 
gel (Iivanainen et al., 2003). Constituents of the degraded BM, fibrin, and EC-produced 
extracellular matrix (ECM) components then form a provisional matrix that ECs invade with 
guidance from both growth factors and matrix proteins. Once through the provisional 
matrix, the endothelial sprout further invades the interstitial matrix, which is composed of 
many proteins including fibrillar collagens (such as collagen I) and fibronectin. These 
proteins may also promote angiogenesis, collagen I for example, has pro-angoigenic effects 
(Davis and Senger, 2005; Senger et al., 2002). The signals from the ECM are transmitted by 
cell-surface expressed adhesion receptors called integrins, which bind to different ECM 
proteins in a specific manner (Stupack and Cheresh, 2004). In conjunction with the fusion of 
newly formed vessel sprouts to allow perfusion, the BM reassembles and pericytes are 
recruited to the vessel. ECs recruit pericytes by secreting PDGF, which binds to the PDGF-
receptor expressed on pericytes; this process is crucial for vessel stabilization, and lack of 
pericyte engagement causes remodelling defects and leaky vessels (Uemura et al., 2002) 
3.4 Role of Integrin in endothelial-cell dynamics during angiogenesis 
Integrins are heterodimeric transmembrane glycoproteins consisting of non-covalently 
associated  and  subunits, and they promote cell-matrix adhesion and migration on the 
surrounding ECM. Integrins have no intrinsic enzymatic or kinase activity, but activate 
signaling pathways by co-clustering with kinases and adaptor proteins in a focal adhesion 
complex comprising: protein kinases such as FAK and Src; adaptor proteins such as Shc; 
signaling intermediates such as GTPases of the Rho family; and actin-binding cytoskeletal 
proteins such as talin, -actinin, paxillin, tensin and vinculin (Mitra et al., 2005; Mitra and 
Schlaepfer, 2006). Integrin signaling promotes cell migration, proliferation and survival 
(Avraamides et al., 2008). Eighteen ┙ and eight ┚ subunits can associate to form 24 unique 
integrin heterodimers. EC integrins that regulate cell growth, survival and migration 
during angiogenesis include heterodimers ┙1┚1, ┙2┚1, ┙4┚1, ┙5┚1, ┙6┚1, ┙6┚4, ┙9┚1, ┙v┚3 
and ┙v┚5 (Avraamides et al., 2008). Integrin ┙v┚3 (a receptor for RGD-containing ECM 
proteins such as vitronectin, fibronectin, fibrinogen and osteopontin) was the first ┙v 
integrin shown to regulate EC survival and migration during angiogenesis. The 
expresssion of ┙v┚3 integrin on resting ECs is negligible, but is upregulated by the 
presence of angiogenic growth factors such as bFGF, TNF┙ and IL8 (Brooks et al., 1994). 
Integrin ┙v┚3 also regulate pathological angiogenesis during processes such as wound 
healing. The VEGFR2–┙v┚3-integrin association is important for full VEGFR2 signaling 
activity, for activation of p38MAPK and FAK, and for the recruitment of actin-binding 
vinculin as needed to initiate EC migration (Mahabeleshwar et al., 2008). The ligation of 
endothelial ┙v┚3 integrin has also been shown to activate FAK, Src, and other kinases, 
resulting in cell proliferation, differentiation and migration (Eliceiri et al., 2002). Whereas 
┙v┚3 dimers initiate angiogenesis in response to bFGF and TNF┙, the related integrin 
┙v┚5 is required for TNF┙- and VEGF-mediated angiogenesis (Friedlander et al., 1995). ┚1 
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integrin, which pairs with variety of  integrin subunits, plays an important role in 
angiogenesis. Mice with EC-specific deletion of ┚1 integrin die during embryonic stages 
due to severe vascular defects (Tanjore et al., 2008). Matrix-bound VEGF induces the 
formation of a complex between VEGFR2 and ┚1 integrin, which leads to prolonged 
phosphorylation of VEGFR2 at TYR 1214 and association of ┚1 integrin with focal 
adhesions (Chen et al., 2010). 
Fibronectin secreted by ECs is a key ECM component. It is deposited by ECs during 
normal and tumor angiogenesis (Clark et al., 1982; Kim et al., 2000). Fibronectin interacts 
with integrins such as ┙5┚1, ┙v┚5 and ┙v┚3 (Plow et al., 2000). During embryonic 
vascular development, as well as during tumor angiogenesis, the ECM protein fibronectin 
serves as an adhesive support and signals through ┙5┚1 integrin to regulate the 
spreading, migration and contractility of ECs (Francis et al., 2002). Although the 
expression of ┙5┚1 in quiescent endothelium is low, it is upregulated by exposure to a 
subset of angiogenic stimuli including bFGF, IL8 and the ECM protein (Kim et al., 2000). 
Integrin ┙5┚1 promotes EC migration and survival in in vivo and in vitro models of 
angiogenesis by suppressing the activity of protein kinase A (PKA) (Kim et al., 2000b(Kim 
et al., 2002). Further, our recent study has demonstrated that integrin ┙5┚1 recycling is 
essential for EC adhesion and migration on fibronectin (Tiwari et al., 2011), a process 
required during angiogenesis. Integrin ┙5┚1 promotes the formation of focal adhesions 
and signaling through FAK (Schlaepfer and Hunter, 1998), which is required for EC 
migration (Mitra et al., 2005). The reduction in EC surface associated adhesion through 
integrin ┙5┚1 in the context of impaired recycling leads to further reduction in total and 
activated FAK (Tiwari et al., 2011). During embryogenesis, integrin ┙5 is required for the 
development of early blood vessels and other tissues, as revealed by the fact that ┙5 
integrin-deficient mice exhibit a mesodermal defect and are embryonic lethal (Yang et al., 
1993). Integrin ┙4┚1, another fibronectin receptor, affects the adhesion and extravasation 
of lymphocytes by binding to VCAM1, a member of the immunoglobulin superfamily, 
that is expressed on inflamed ECs. Deletion of integrin ┙4 in a mouse model leads to 
defects in plancentation, heart development and coronary artery development, and thus 
to embryonic lethality (Yang et al., 1995). Integrin ┙4┚1 promotes adhesion of the 
endothelium to VCAM1-expressing vascular smooth muscle cells during blood vessel 
formation (Garmy-Susini et al., 2005). Integrin ┙4┚1–VCAM1 facilitates cell-cell 
attachment between ECs expressing the pericyte chemoattractant PDGF and pericytes 
expressing VEGF, in response to growth and survival signals that emanate from each cell 
type during angiogenesis (Garmy-Susini et al., 2005). Integrin ┙9┚1 is another fibronectin-
binding integrin known to have role in angiogenesis (Vlahakis et al., 2007). Although 
structurally similar to integrin ┙4┚1, integrin ┙9┚1 can bind to a number of ECM proteins 
and cell-surface receptors including tenascin C, thrombospondin, osteopontin, fibronectin, 
VCAM1 and other ligands (Liao et al., 2002; Marcinkiewicz et al., 2000; Staniszewska et 
al., 2007). ┙4┚1 binds only to VEGF, and promotes VEGFA-induced angiogenesis. ┚1 
integrin, which pairs with variety of alpha integrin subunits, plays a key role in 
angiogenesis.  Mice with an EC-specific deletion of ┚1 integrin die at embryonic stages 
due to a severe vascular defect (Tanjore et al., 2008). Matrix-bound VEGF induces the 
formation of complex between VEGFR2 and ┚1 integrin, which leads to prolonged 
phosphorylation of VEGFR2 at TYR 1214 and to an association of ┚1 integrin with focal 
adhesions (Chen et al., 2010). 
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4. Membrane trafficking 
Membrane trafficking is an active process that relocates proteins from one region of a cell to 
another, and contributes to the regulation of cell migration (Ulrich and Heisenberg, 2009). 
Signaling by the membrane-resident proteins/receptors is regulated by their availability at 
the cell surface or correct locations that are controlled by membrane trafficking events. The 
trafficking of membrane receptors and their signaling are intertwined: trafficking itself 
affects signal transduction, and signaling by RTKs regulates the trafficking machinery 
(Sorkin and von Zastrow, 2009). The secretory and endocytic pathways, which are made up 
of a network of membrane-bound compartments, modify newly synthesized proteins, 
deliver them to their appropriate locations, and regulate the uptake and turnover of those 
that are targeted to the cell surface. Trafficking accomplishes the specific and regulated 
transfer of molecules between distinct membrane-enclosed organelles. The transport process 
involves the budding of vesicular or tubular carriers from donor membranes, followed by 
their delivery to specific acceptor membranes. Budding requires the formation of cargo-
laden vesicles or tubules at a donor compartment, and also the involvement of (i) specific 
coat proteins like COPI or COPII; (ii) adaptor proteins such as clathrin, AP-1, 2, 3; and (iii) 
membrane-deforming proteins like Bar-family proteins (Doherty and McMahon, 2009). The 
cargo-containing donor vesicle then docks to the acceptor compartment with the help of rab 
GTPases and a tether. Finally, fusion of the donor and acceptor membranes for the delivery 
of the cargo is accomplished with the help of N-ethylmaleimide-sensitive factor (NSF)-
attachment protein receptor (SNARE) protein complexes (Jahn and Scheller, 2006; Sudhof 
and Rothman, 2009).  
4.1 Biosynthetic/secretory pathway 
After being synthesized in the cytoplasm, new proteins are translocated to the endoplasmic 
reticulum (ER) (Lee et al., 2004) and then move to Golgi via membranous vesicles. After 
moving through the cis and medial cisternae of the Golgi, the ER-derived cargoes move to 
trans-Golgi cisternae, where the proteins destined for secretion or presentation on the PM 
are packed into secretory vesicle that subsequently fuse with the PM (Emr et al., 2009). The 
Golgi apparatus is the major sorting compartment of the cell; its cargo is sorted not only to 
the PM for presentation or secretion, but also to endosomes and lysosomes, or back to the 
ER (Emr et al., 2009). 
4.2 Endocytic and exocytic pathways 
The endocytic pathway regulates internalization and recycling of proteins internalized from 
the PM, through a variety of mechanisms, to early and/or late endosomes. Depending on 
the receptor type and the particular requirements of a particular cell, protein from the 
endosomes are either sorted to the lysosome, a major degradation site for both internalized 
and cellular proteins, or recycled back to the PM (Doherty and McMahon, 2009).  
Efficient protein trafficking within endomembrane system is further regulated by cross-talk 
between the two pathways. Endosomal and lysosomal proteins that maintain their integrity 
and functionality shuttle from the ER, via the Golgi, to endosomes and lysosomes (Ghosh et 
al., 2003). In polarized cells, movement of the proteins from one side of the cell to the other, 
via the transcytotic pathway, involves both the biosynthetic/secretory and the 
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endo/exocytic routes (Tuma and Hubbard, 2003). Thus, the membrane trafficking events 
control the cell communication network connected with signaling events, determining not 
only the intensity and duration, but also the final biological outcome.  
The membrane trafficking process is also important for the signaling activities required 
for cell survival and migration during the normal physiological response, as well as for 
those that take place during angiogenesis. In ECs, modulation of receptor tyrosine activity 
through endocytosis and vesicle trafficking affects downstream targets such as 
endothelial nitric oxide synthase (eNOS) and VE-cadherin. Further, activation of RTKs 
results in the dissolution of EC–specific adhesion through endocytosis of VE-cadherin, 
thereby promoting cell migration and vascular permeability (Mukherjee et al., 2006). 
Directional cell migration requires the trafficking of adhesion and growth factor receptors 
including VEGFR2, which is involved with angiogenesis (Lanahan et al., 2010). The 
angiogenic signals generated in response to VEGFR2 receptor activation are highly 
regulated by sorting pathways during intracellular trafficking (Manickam et al., 2011). 
VEGFR2 signaling is regulated by a broad range of angiogenic regulators that in turn 
regulates receptor trafficking through the endosomal system (Manickam et al., 2011; Scott 
and Mellor, 2009). Rab GTPases regulate key events in VEGFR2 trafficking between the 
PM, early endosomes and late endosomes (Bruns et al., 2009). In addition, the Golgi 
(which is the central hub for membrane trafficking across the mammalian cell) 
coordinates the cell-surface expression of VEGFR2 by regulating the secretory transport of 
newly synthesized VEGFR2 (Manickam et al., 2011). 
4.3 Endocytic trafficking of VEGFR2 
Resting ECs have two pools of VEGFR2: a stable cell-surface pool that can form a complex 
with VE-cadherin at cell-cell junctions and does not undergo rapid internalization 
(Lampugnani et al., 2006), and a pool that continuously cycles between the surface and 
sorting endosomes and is independent of VEGF binding (Gampel et al., 2006). The VEGFR2 
is associated with the caveolin-containing and cholesterol-enriched membrane microdomain 
(Labrecque et al., 2003). Binding of VEGF to extracellular domain of VEGFR2 triggers 
internalization of receptor subsequent to its dimerization and phosphorylation at TYR1054 
and TYR1059. Upon activation, VEGFR2 dissociates from caveolin and transported to 
endosomes (Salikhova et al., 2008). Multiple modes of VEGFR2 internalization exist, since 
VEGF-stimulated endocytosis of VEGFR2 is clathrin-dependent (Lampugnani et al., 2006), 
and VEGFR2 is known to be translocated to perinuclear caveosomes through caveolar 
endocytosis (Bauer et al., 2005; Labrecque et al., 2003). Thus, the intracellular distribution of 
VEGFR2 depends on VEGF stimulation. Endosomal trafficking and the signaling of VEGFR2 
is dependent on the Rab5a protein, a Ras-related small GTPase associated with early 
endosomes (Jopling et al., 2009). Depletion of Rab5a enhances VEGFR2 tyrosine 
phosphorylation and MAPK signaling, whereas overexpression of a Rab5a GTPase-deficient 
(constitutively active mutant, Q79L) causes VEGFR2 accumulation within endosomes 
(Jopling et al., 2009). Rab7a GTPase regulates VEGFR2 trafficking from early to late 
endosomes. Rab7a depletion is inhibitory whereas Rab5a depletion is stimulatory for EC 
migration (Jopling et al., 2009). VEGF stimulation also can increase the rate of VEGFR2 
recycling from sorting endosomes. The vesicles containing VEGFR2 /Src complex traffic to a 
late endosomal compartment after a longer duration (30 mins) of VEGF stimulation (Gampel 
et al., 2006). Since Src is an important downstream target of VEGFR2 in an angiogenesis and 
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vascular permeability pathway (Zachary, 2003), it is believed that recycling of VEGFR2/Src 
to the PM would sensitize pro-angiogenic signals. VEGF stimulation direct VEGFR2 from 
sorting endosomes to late endosomes finally directs it toward lysosomes for degradation 
(Gampel et al., 2006). 
Regulation of VEGFR2 degradation is important for angiogenesis since VEGFR2 down-
regulation controls the sensitivity of ECs to VEGF stimulation. Reports of VEGFR2 
degradation upon VEGF stimulation are varied. One study suggests that VEGFR2 
degradation is complete upon VEGF A stimulation (Ewan et al., 2006), whereas another 
study revealed degradation of only 30-40% of the total  receptor population (Gampel et al., 
2006). Degradation of activated VEGFR2 is promoted by its ubiquitination by c-Cbl, a 
protein that forms a complex with phospholipase C┛1 (PLC┛1), a mediator of VEGFR2 
signaling (Singh et al., 2007). VEGFR2 trafficking can also be regulated by the co-receptors 
such as VEGFR1 and NRP1, which can interact with VEGFR2. VEGFR1 is ubiquitylated 
upon VEGF stimulation and recruits Cbl (Kobayashi et al., 2004). As discussed above, 
VEGFR1 forms a heterodimer with VEGFR2 upon VEGF binding, so that the decision for 
sorting of VEGFR2 along a degradative pathway could be influenced by VEGFR1. NRP1, 
one of the other VEGFR2 co-receptors, which forms a complex with VEGFR2 upon VEGF 
binding, could stabilize VEGFR2 on the EC surface since loss of NRP1 increases the 
degradation of VEGFR2 upon VEGF stimulation (Holmes and Zachary, 2008).  
4.4 Secretory transport of VEGFR2 
Although the endocytic transport of VEGFR2 has been characterized in detail, the reports on 
secretory transport, i.e transport of newly synthesized VEGFR2, are scant. The Golgi 
apparatus regulates the trafficking of newly synthesized VEGFR2, since the Golgi receives 
newly synthesized proteins and lipids from the endoplasmic reticulum (ER), the central 
organelle in which trafficking-route decisions are made. Recently, studies from our group 
demonstrated that a significant amount of VEGFR2 is present in the Golgi apparatus, and 
that VEGF mobilizes this pool from the Golgi compartment (Manickam et al., 2011). The 
post-Golgi trafficking of cargo occurs in vesicular fashion, where the cargo-loaded vesicles 
bud from Golgi, delivering the cargoes to their target destinations by membrane fusion 
events. Membrane fusion steps in eukaryotic cells require SNAREs (Chen and Scheller, 2001; 
Hong, 2005). The SNAREs are classified into 2 major groups based on the presence of a 
glutamine (Q SNAREs or t-SNAREs) or an arginine (R SNAREs or v-SNAREs) in the center 
of the SNARE motif. The trans-Golgi network- and endosome-localized t-SNARE syntaxin 6 
(STX6), but not syntaxin 10 and syntaxin 16, regulates secretory transport of VEGFR2 as well 
as VEGF-induced angiogenic processes (Manickam et al., 2011). Earlier studies 
demonstrated that STX6 participates in post-Golgi transport of components of membrane 
microdomains to the PM (Choudhury et al., 2006). Inhibition of STX6 either by loss-of-
function approaches, applying an siRNAs against STX6 or by expressing the inhibitory, 
cytosolic domains of STX6 interferes with trafficking of Golgi-resident pool of VEGFR2 and 
targets it to lysosomes for degradation in human ECs, as described in model (Figure 7). 
Further, inhibition of STX6 in cell culture reduced VEGF-induced cell proliferation, cell 
migration, and vascular tube formation (Manickam et al., 2011). Thus, the t-SNARE STX6 
plays a crucial role in maintaining cellular VEGFR2 levels and, subsequently, in 
physiological processes associated with VEGF-mediated angiogenesis. 
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Fig. 7. Schematic summary of VEGFR2 trafficking. In endothelial cells, VEGFR2 is enriched 
in the plasma membrane, endosomes and Golgi apparatus. These VEGFR2 pools are 
maintained by endocytic and secretory transport pathways. The subcellular localization of 
VEGFR2 is essential for VEGF mediated signaling and angiogenesis, and is regulated by 
syntaxin 6, which colocalizes with VEGFR2 at the Golgi apparatus and endosomes. When 
syntaxin 6 function is inhibited, the cellular pool of VEGFR2 is depleted as a consequence of 
enhanced degradation in lysosomes. Syntaxin 6 contributes to trafficking of VEGFR2 from 
the Golgi and/or endosomes and the maintenance of proper levels of this receptor in 
different subcellular compartments required for efficient receptor signaling and 
angiogenesis. (Modified from Manickam et al., 2011. Blood 117, 1425-1435. © the American 
Society of Hematology.) 
4.5 VEGFR2 trafficking and angiogenesis 
The process of angiogenesis is regulated by the response of VEGFR2 to VEGF binding. The 
availability of VEGFR2 at the PM may directly control the signaling response of ECs to 
VEGF for the onset of pro-angiogenic events. Thus, the trafficking mechanisms, such as 
secretory transport, recycling or degradation that affects the surface level VEGFR2, would 
determine the response of ECs to VEGF during angiogenesis.  The EC-surface proteins that 
stabilize VEGFR2 at the plasma membrane contribute to the VEGF-driven cellular response 
during angiogenesis. A reduction in the engagement of VE-cadherin with ECs present in the 
stable vasculature leads to a reduction in surface levels of VEGFR2, thus reducing the 
sensitivity of ECs to VEGF (Lampugnani et al., 2006). The trafficking of VEGF receptors 
becomes more important under pathological conditions such as wound healing or ischemic 
heart disease, which may require rapid recycling and/or secretory transport of VEGF 
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receptors to the surface, ensuring continuous activation of the VEGF/VEGFR pathway to 
guide angiogenic events. 
As discussed above, a study by our group (Manickam et al., 2011) demonstrated that 
enhanced VEGFR2 degradation due to reduced secretory transport of VEGFR2 from the 
Golgi to PM (due to lack of functional STX6) leads to reductions in VEGF-induced 
proliferation, migration, and tube formation. Such in vitro effects may be responsible for 
reduced VEGFA-induced angiogenesis in the context of interference with STX6 function via 
adenoviral gene transfer of cytosolic domain of STX6 (STX6-cyto, inhibitory form) in ear 
angiogenesis assay in nude mice (Figure 8). This ear angiogenesis model demonstrated that 
trafficking of VEGFR2 is essential for angiogenesis. Also, in our most recent study, we 
demonstrated that STX6 is essential for maintenance of EC surface-localized integrin ┙5┚1, 
which plays a crucial role in angiogenesis (Tiwari et al., 2011). The finding that expressing a 
cytosolic form of STX6 significantly blocks VEGF-induced angiogenesis raises the prospect 
that pharmacologic manipulation of STX6 function in the setting of vascular disorders may 
be an effective therapeutic tool.  
 
Fig. 8. Mice Ear Angiogenesis Assay: Representative images showing gross appearance of 
angiogenesis in mock, syntaxin 6-cyto– or syntaxin 16-cyto–injected mouse ears, 5 days 
before adenovirus expressing VEGF164 (Ad-VEGF164) administration. Nude mice (Nu/Nu 
strain) were given 2 injections under anesthesia. The first set of injections (1st) was PBS, 
syntaxin 6-cyto, or syntaxin 16-cyto. The second (2nd) was PBS or Ad-VEGF164, and given 2 
days later at the site of first injection. At 7 days after the first set of injections, animals were 
euthanized and the ears were photographed. (from Manickam et al., 2011. Blood 117, 1425-
1435. © the American Society of Hematology). 
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5. Conclusions 
Angiogenesis is regulated by VEGF-stimulated sensitization of the VEGF receptor and 
subsequent signaling events that are required during this process. Intracellular trafficking of 
VEGFR2 controls the VEGF signals that govern angiogenesis. Deciphering the mechanism 
underlying this trafficking and the roles of mediators in the transport of other VEGF 
receptors, as well as identifying other angiogenic components that play a role in the 
formation of new vessels, may provide better insight into angiogenesis. Syntaxin 6-
regulated membrane trafficking events control outside-in signaling via the haptotactic and 
chemotactic mechanisms that regulate integrin 51-mediated EC movement on fibronectin 
and VEGF-mediated VEGFR2 signaling– important components of the angiogenic process 
(Manickam et al., 2011; Tiwari et al., 2011). A great deal has been deciphered about 
angiogenesis-related signaling pathways, but a detailed investigation of the intracellular and 
membrane trafficking of molecules associated directly or indirectly with angiogenesis 
would add to our knowledge of the angiogenic process, as well as help us to design 
therapeutic strategies for pathological angiogenesis therapeutic strategies for pathological 
angiogenesis. 
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